Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Louis M. Staudt"'
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Autor:
Brendan Hodkinson, Louis M. Staudt, George E. Wright, Martin Shreeve, Sriram Balasubramanian, Yue Fan, Wyndham H. Wilson, Da-Wei Huang, Jessica Vermeulen
Publikováno v:
Cancer cell. 39(12)
Summary In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency that is targetable by ibrutinib. A phase III trial (“P
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in
Autor:
Jeremy S. Abramson, Heiko Schöder, Wyndham H. Wilson, Richard I. Fisher, Nancy L. Bartlett, Matthew J. Maurer, Levi Pederson, John P. Leonard, Jane N. Winter, Nishitha Reddy, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Susan Mathew, Julie E. Chang, Ajay K. Gopal, Jonathan W. Friedberg, Brad S. Kahl, Amy Chadburn, Kristy L. Richards, Brandelyn N. Pitcher, Bruce D. Cheson, Mei Yin C. Polley, Andrew D. Zelenetz, Eric D. Hsi, Sin-Ho Jung
Publikováno v:
Journal of Clinical Oncology. 37:1790-1799
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, v
Autor:
M. Andrew Monticelli, Raquel Izumi, Jeff P. Sharman, Joseph Roswarski, Jacob F. Collen, Jigar V. Desai, Louis M. Staudt, Michail S. Lionakis, Marissa A. Zarakas, Andre Goy, Michael Roshon, Ahmed Hamdy, Stephen H. Wrzesinski, José Baselga, George E. Wright, Keith M. Rose, Mark Roschewski, Wyndham H. Wilson, Kevin K. Chung
Publikováno v:
Science Immunology
Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.
Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bru
Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bru
Autor:
Shaghayegh Soudi, Constance Namirembe, Andrew J. Mungall, Nancy L. Bartlett, Jeffrey M. Bethony, Louis M. Staudt, Julie M. Gastier-Foster, B. M. Grande, Manuela Cruz, Nicholas B. Griner, Timothy C. Greiner, Steven H. Reynolds, Ryan D. Morin, Fabio E. Leal, Kostiantyn Dreval, Wyndham H. Wilson, Anthony C. Bryan, Daniela S. Gerhard, John D. Irvin, German Ott, Thomas G. Gross, Charles G. Mullighan, Karen Mungall, Jeremy S. Abramson, Martin D. Ogwang, David Scott, Elaine S. Jaffe, Ariela Noy, Maureen A. Dyer, Laura K. Hilton, Jay Bowen, S M Mbulaiteye, Nancy L. Harris, J Martín, Marco A. Marra, Alina S. Gerrie, Jackson Orem, Steven H. Swerdlow, Marie-Reine Martin, Hilary Petrello, Nicole Thomas, Corey Casper, Jasper Wong, Alexandra Traverse-Glehen
Publikováno v:
Blood. 138:806-806
Introduction: Burkitt lymphoma (BL) accounts for approximately 50% of all pediatric non-Hodgkin lymphomas compared to 1-2% in adults. Adult BL (aBL) remains a poorly understood entity and its relationship to pediatric BL (pBL) and to DLBCL has not be
Autor:
Wyndham H. Wilson, Milos D. Miljkovic, James D. Phelan, Anna Marie Juanitez, Amy Hillsman, Jagan R. Muppidi, Mark Roschewski, Amynah Pradhan, Michele Ceribelli, Seth M. Steinberg, Craig J. Thomas, Louis M. Staudt, Stefania Pittaluga, Rahul Lakhotia, Christopher Melani, Elaine S. Jaffe
Publikováno v:
Blood. 138:3537-3537
Background: Mantle cell lymphoma (MCL) is a biologically and clinically heterogenous B-cell lymphoma that is generally incurable with standard therapies. Novel targeted agents can disrupt key survival pathways in MCL such as regulation of apoptosis (
Autor:
Rahul Lakhotia, Jillian Simard, James D. Phelan, Jagan R. Muppidi, Elaine S. Jaffe, Lydia L. Chou, Louis M. Staudt, Stefania Pittaluga, Michail S. Lionakis, Andrea Nicole Lucas, Wyndham H. Wilson, Seth M. Steinberg, Matthias Holdhoff, Christopher Melani, Mark Roschewski, John A. Butman, Michael Glantz
Publikováno v:
Blood. 136:24-25
Background: Secondary CNS B-cell lymphomas (SCNSL) are aggressive lymphomas with a very poor prognosis. Genetic subtypes of DLBCL with CNS tropism are enriched for chronic active B-cell receptor signaling and may respond to BTK inhibition (BTKi). CLL
Autor:
Rahul Lakhotia, William D. Figg, Christopher Melani, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson, Sarah Evans, Jagan R. Muppidi, Louis M. Staudt, Stefania Pittaluga, Lydia L. Chou, Mark Roschewski, James D. Phelan
Publikováno v:
Blood. 136:39-40
Introduction Follicular lymphoma (FL) has a highly variable clinical course. Chemoimmunotherapy can induce durable remissions, but ~20% relapse early. The PI3K pathway is central to FL biology and multiple PI3K inhibitors (PI3Ki) are approved for FL,
Autor:
Wyndham H. Wilson, William D. Figg, Andrea Nicole Lucas, Rahul Lakhotia, Elaine S. Jaffe, Lydia L. Chou, Matthias Holdhoff, Catherine Lai, Christopher Melani, Cody J. Peer, Michail S. Lionakis, Jan Drappatz, S. Percy Ivy, Richard F. Little, John A. Butman, Louis M. Staudt, Stefania Pittaluga, Michael Glantz, James D. Phelan, Mark Roschewski, Seth M. Steinberg
Publikováno v:
Blood. 136:12-13
Background: Primary DLBCL of the CNS (PCNSL) relies on chronic active B-cell receptor (BCR) signaling. Ibrutinib targets BCR signaling through BTK inhibition (BTKi), which may also impair innate immunity. We showed that ibrutinib and temozolomide, et